TXG - Rasio cepet 10x Genomics, Inc.

This chart of the market valuation for 10x Genomics, Inc. (TXG) demonstrates the 5.17 metric, highlighting the specifics of its cell analysis systems business. Revenue is based on the sale of high-cost instruments followed by the sale of high-margin consumables. While success relies on the funding of research centers, cash flow stability is guaranteed by the constant demand for unique reagents for every new assay.

The quick ratio measures a company's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding slow-moving inventories. By analyzing changes in quick liquidity, an investor can gauge the financial reserve of 10x Genomics, Inc. (TXG) required to protect its patent leadership and compete against tech startups amidst the high cost of upgrading laboratory infrastructure.